Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ENZ 
Enzo Biochem Inc (ENZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ENZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -35.19% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.42M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 148951 | Beta 0.77 | 52 Weeks Range 0.31 - 1.19 | Updated Date 04/2/2025 |
52 Weeks Range 0.31 - 1.19 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 117.65% | Basic EPS (TTM) -0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate - | Actual -0.0294 |
Profitability
Profit Margin -73.25% | Operating Margin (TTM) -21.84% |
Management Effectiveness
Return on Assets (TTM) -7.46% | Return on Equity (TTM) -12.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -19342047 | Price to Sales(TTM) 0.6 |
Enterprise Value -19342047 | Price to Sales(TTM) 0.6 | ||
Enterprise Value to Revenue 0.26 | Enterprise Value to EBITDA -3.27 | Shares Outstanding 52402800 | Shares Floating 36435670 |
Shares Outstanding 52402800 | Shares Floating 36435670 | ||
Percent Insiders 21.68 | Percent Institutions 34.8 |
Analyst Ratings
Rating - | Target Price 5.5 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Enzo Biochem Inc
Company Overview
History and Background
Enzo Biochem Inc. was founded in 1976. It initially focused on genetic engineering and has evolved into a biotechnology company developing, manufacturing, and marketing diagnostic and research products.
Core Business Areas
- Enzo Clinical Labs: Provides clinical laboratory services, offering a broad range of diagnostic tests. Focuses on high-complexity testing, including molecular diagnostics and cytology.
- Enzo Life Sciences: Develops, manufactures, and markets a wide range of research products including labeling and detection reagents, assay kits, and biomolecules, serving academic, government, and biopharmaceutical researchers.
- Enzo Therapeutics: Focused on research and development of novel therapeutics, primarily in the areas of immune modulation.
Leadership and Structure
Elazar Rabbani is the CEO of Enzo Biochem Inc. The company operates with a structure involving various departments focusing on research, manufacturing, sales, and clinical lab services.
Top Products and Market Share
Key Offerings
- AMPIPROBE: A line of products focused on nucleic acid labeling and detection. These kits are used in various research applications including microarray analysis, FISH, and Northern/Southern blotting. There isn't readily available exact market share data. Competitors include Thermo Fisher Scientific, Bio-Rad, and Agilent Technologies.
- GENFLEX ARRAYER: An instrument used for automated microarray printing. Limited market share data available. Thermo Fisher Scientific and Agilent Technologies are competitors.
- Enzo Clinical Labs Diagnostic Tests: A broad range of diagnostic tests. Competition is significant, with Quest Diagnostics and Labcorp being major players. Enzo Clinical Labs is smaller compared to the national labs.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The diagnostic market is growing driven by increasing demand for personalized medicine and preventative care.
Positioning
Enzo Biochem Inc. positions itself as an integrated diagnostics and life sciences company. Its competitive advantages include a portfolio of patented technologies and a vertically integrated business model.
Total Addressable Market (TAM)
The global molecular diagnostics market is projected to reach several billion dollars. Enzo Biochem Inc. is positioned to capture a portion of this market through its diagnostic offerings and R&D efforts. It's TAM includes the life sciences market as well, making the TAM very large.
Upturn SWOT Analysis
Strengths
- Vertically integrated business model
- Patented technologies
- Clinical laboratory services
- Life sciences product portfolio
Weaknesses
- Financial performance
- Limited market share in key segments
- Heavy reliance on patents
- Fluctuations in sales performance.
Opportunities
- Expansion of diagnostic testing services
- Development of new therapeutic products
- Partnerships and collaborations
- Increasing demand for personalized medicine
Threats
- Competition from larger players
- Regulatory changes
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- LH
- DGX
- TMO
- ILMN
Competitive Landscape
Enzo Biochem Inc. faces stiff competition from larger, more established companies with greater resources. Enzo's vertically integrated model and patented technologies offer some competitive advantages.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Enzo Biochem Inc.'s growth has been inconsistent over the past several years.
Future Projections: Future growth projections depend on successful execution of strategic initiatives and market conditions.
Recent Initiatives: Recent strategic initiatives include focusing on new diagnostic test development and expanding sales channels.
Summary
Enzo Biochem Inc. is a biotechnology company operating in diagnostics and life sciences, it shows inconsistent growth. The vertically integrated model and patented technologies offer some strength and the clinical labs have the potential to grow. However, it needs to address its financial performance and market share limitations compared to larger competitors. The company needs to capitalize on opportunities to grow in the precision medicine area.
Similar Companies
DGX
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
ILMN
Illumina Inc
ILMN
Illumina Inc
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Market Research Reports
- Publicly available company information.
Disclaimers:
The data provided is for informational purposes only and does not constitute investment advice. Market share and financial data are estimates and may vary. The AI-based rating is generated using an algorithm and should be used as one factor in your investment decision. Please see SEC Filings for more up to date information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enzo Biochem Inc
Exchange NYSE | Headquaters Farmingdale, NY, United States | ||
IPO Launch date 1980-06-12 | CEO & Director Ms. Kara Cannon | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 125 | Website https://www.enzo.com |
Full time employees 125 | Website https://www.enzo.com | ||
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.